Drug · Small Molecule

Meloxicam

CI-DRUG-00000372Explore in graph →NCIt C61439 CHEMBL599 CIViC Approved

Regulatory

Approvals (4)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory4 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required. XIFYRM contains meloxicam, which is an NSAID, and is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required. ( 1 )	approved	Jun 5, 2025	openfda
US FDA	—	QAMZOVA is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, QAMZOVA alone is not recommended for use when rapid onset of analgesia is required. QAMZOVA contains meloxicam, which is an NSAID, and is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, QAMZOVA alone is not recommended for use when rapid onset of analgesia is required. ( 1 )	approved	Apr 22, 2025	openfda
US FDA	—	Efficacy supplement 2005-08-11 (see label)

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	1	1	1	4	4	US	Jun 1, 2004	2004-02
Hodgkin Lymphoma	Phase2	Phase 2	0	0	0	1	0	—	—	2013-10
Multiple Myeloma	Phase2	Phase 2	0	0	0	2	0	—	—	2013-10
Non-Hodgkin Lymphoma	Phase2	Phase 2	0	0	0	2	0	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CTNNB1 S45F1
Meloxicam	Desmoid Fibromatosis

Clinical trials

Trials with this intervention (4)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–4 of 4 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07200544	Meloxicam in Mohs Micrographic Surgery	recruiting	Phase 4	300	University of OklahomaOTHER	1	Dec 15, 2025	clinicaltrials
NCT02078102	A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma	completed	Phase 2	38	Sherif S. Farag

Molecule

Record

Kind: Small Molecule
Mechanism: Cyclooxygenase-2 inhibitor
Targets: 1 gene
UNII: VG2QF83CGL
Aliases: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, Acticam, Anjeso, Contacera, Coxicam, Emdocam, Flexicam, Inflacam, Loxicom, Loxitab, Melfax, Melosus, Melovem, Meloxicam, Meloxicam component of zeleris, Meloxicam component of zynrelef, Meloxidolor, Meloxidyl, Meloxivet, Meloxoral, Metacam, Mobec, Mobic, Mobicox, Movalis, Movatec, N-1539, N1539, Novaquin, Novem … (+11)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.